HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

Hercules Capital

ARCH Venture Partners

Hillhouse Capital Group

Celgene

Trinitas Capital

Magnetic Ventures

Monashee Investment Management

Huizenga Capital Management

Bristol-Myers Squibb

HiberCell

We highlighted preclinical data for HC-7366 in combination with standard of care agents in AML at the 65th ASH annual meeting.  Read the full announcement below.

https://lnkd.in/en8D2W_C


We're excited to announce our clinical collaboration with Merck to evaluate HC-7366 in combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)! Read the full announcement below.

https://lnkd.in/eaX2NBD2

We're excited to announce the successful completion and interim results of our Phase 1 study of HC-5404 in advanced solid tumors and to map a forward path as monotherapy and in combinations! Read the full announcement below.

https://lnkd.in/e7FBRyhx


We're excited to announce the dosing of our first patient in a Phase 1b study exploring the novel combination of odetiglucan with CDX-1140 in the PDAC maintenance setting.  

This an important step for our investigational therapeutic, odetiglucan, and for HiberCell as we advance novel therapeutics targeting adaptive stress and immune modulation.  For more information, please see our press release. 

https://lnkd.in/eTETSs8g

The HiberCell team is looking forward to our poster presentations on two of our novel candidates currently in clinical trials at #AACR2023 in Orlando

https://lnkd.in/eaDcrC5q  #HC5404 #HC7366 #GCN2 #PERK #aacr2023 #oncology #clinicaltrials

Hibercell Inc is pioneering the development of differentiated treatment approaches to target mechanisms that arise as a result of adaptive stress induction in cancer cells, with the aim of enabling patients to live longer, cancer-free lives.

COM:HIBERCELL

Hibercell Inc

Filings Not Available